IAM
RIGL icon

Ion Asset Management’s Rigel Pharmaceuticals RIGL Stock Holding History

Ion Asset Management’s Portfolio RIGL Stock Details RIGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-333,524
Closed -$12.1M – 44
2021
Q3 		$12.1M Sell
333,524
-14,432
-4% -$568K 1.66% 16
2021
Q2 		$15.1M Sell
347,956
-15,257
-4% -$576K 1.86% 14
2021
Q1 		$12.4M Buy
363,213
+180,213
+98% +$7.14M 1.43% 17
2020
Q4 		$6.41M Buy
+183,000
New +$5.3M 0.73% 18

Other funds holding RIGL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
TA
Tamarack Advisers Carlsbad, California $2.12M AUM 58.09% 1-Year Est. Return

Ion Asset Management's RIGL Position: Q4 2021 in Review

Ion Asset Management sold out of Rigel Pharmaceuticals (RIGL) in Q4 2021, closing a stake of 333,524 shares — an estimated $12.1M sold.

Ion Asset Management first reported a position in RIGL in Q4 2020 and held it in 4 quarters. The position peaked at $15.1M in Q2 2021. 162 funds tracked by Wall St. Rank hold RIGL as of Q4 2021.

  • Ion Asset Management reported no remaining Rigel Pharmaceuticals position as of Q4 2021 after selling out during the quarter.
  • Ion Asset Management sold 333,524 Rigel Pharmaceuticals shares in Q4 2021, an estimated $12.1M.
  • Ion Asset Management first reported a position in Rigel Pharmaceuticals in Q4 2020 and held it in 4 quarters.
  • Ion Asset Management's Rigel Pharmaceuticals position peaked at $15.1M in Q2 2021.
  • 162 funds tracked by Wall St. Rank held Rigel Pharmaceuticals as of Q4 2021.

Based on Ion Asset Management's 13F filing for Q4 2021, filed 14 Feb 2022.